Women's Health Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
International Breast Cancer Study Group, Bern
Review focused on subpopulations and toxicity in trials of aromatase inhibitors
February 5th, 2006
A recent review focused on subpopulations and toxicity in trials of aromatase inhibitors for postmenopausal women. "Hormonal manipulations have been used for more than 100 years for the treatment of metastatic breast cancer and, after definition of the concept of micro-metastases, also in the adjuvant setting. In the postmenopausal population, tamoxifen has played the most important role for almost four decades," stated investigators in Switzerland. S. Dellapasqua and colleagues wrote, "Progestins or the first generation of aromatase inhibitors (AIs) were only marginally used in the adjuvant setting due to their prohibitive toxicity. The new...
Source: Women's Health Law Weekly (2006-02-05)
|
